FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094539666> ?p ?o ?g. }

• W2094539666 endingPage "259" @default.
• W2094539666 startingPage "250" @default.
• W2094539666 abstract "•Development of a rapid, highly efficient, and robust protocol to produce O4+ hOPCs•Generation of iPSCs from primary progressive MS patients•Differentiation of PPMS iPSCs to mature oligodendrocytes in vitro•Successful in vivo myelination from PPMS-iPSC-derived OPCs Multiple sclerosis (MS) is a chronic demyelinating disease of unknown etiology that affects the CNS. While current therapies are primarily directed against the immune system, the new challenge is to address progressive MS with remyelinating and neuroprotective strategies. Here, we develop a highly reproducible protocol to efficiently derive oligodendrocyte progenitor cells (OPCs) and mature oligodendrocytes from induced pluripotent stem cells (iPSCs). Key elements of our protocol include adherent cultures, dual SMAD inhibition, and addition of retinoids from the beginning of differentiation, which lead to increased yields of OLIG2 progenitors and high numbers of OPCs within 75 days. Furthermore, we show the generation of viral and integration-free iPSCs from primary progressive MS (PPMS) patients and their efficient differentiation to oligodendrocytes. PPMS OPCs are functional, as demonstrated by in vivo myelination in the shiverer mouse. These results provide encouraging advances toward the development of autologous cell therapies using iPSCs. Multiple sclerosis (MS) is a chronic demyelinating disease of unknown etiology that affects the CNS. While current therapies are primarily directed against the immune system, the new challenge is to address progressive MS with remyelinating and neuroprotective strategies. Here, we develop a highly reproducible protocol to efficiently derive oligodendrocyte progenitor cells (OPCs) and mature oligodendrocytes from induced pluripotent stem cells (iPSCs). Key elements of our protocol include adherent cultures, dual SMAD inhibition, and addition of retinoids from the beginning of differentiation, which lead to increased yields of OLIG2 progenitors and high numbers of OPCs within 75 days. Furthermore, we show the generation of viral and integration-free iPSCs from primary progressive MS (PPMS) patients and their efficient differentiation to oligodendrocytes. PPMS OPCs are functional, as demonstrated by in vivo myelination in the shiverer mouse. These results provide encouraging advances toward the development of autologous cell therapies using iPSCs. Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the CNS that is distinguished by recurrent episodes of focal inflammatory demyelination and consequent neurological symptoms (relapsing remitting MS [RRMS]). Although relapses usually resolve in spontaneous remission, RRMS can evolve with time into a secondary progressive form characterized by irreversible accumulation of disabilities. Furthermore, patients affected by the most severe primary progressive form (PPMS) experience a steady neurological decline from the onset of the disease (Antel et al., 2012Antel J. Antel S. Caramanos Z. Arnold D.L. Kuhlmann T. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?.Acta Neuropathol. 2012; 123: 627-638Crossref PubMed Scopus (145) Google Scholar). Currently available treatments targeting the immune system are highly effective at reducing or even stopping the intermittent episodes of inflammation, but they do not influence the course of progressive MS. Therapeutic options for PPMS patients are limited to symptomatic treatments and the long-term prognosis is generally poor (Rice et al., 2013Rice C.M. Cottrell D. Wilkins A. Scolding N.J. Primary progressive multiple sclerosis: progress and challenges.J. Neurol. Neurosurg. Psychiatry. 2013; 84: 1100-1106Crossref PubMed Scopus (45) Google Scholar). Clearly, the unsolved challenge in the MS field is to develop neuroprotective and remyelinating strategies for the treatment of progressive MS patients (Hauser et al., 2013Hauser S.L. Chan J.R. Oksenberg J.R. Multiple sclerosis: Prospects and promise.Ann. Neurol. 2013; 74: 317-327Crossref PubMed Scopus (156) Google Scholar). The generation of patient-specific cells from induced pluripotent stem cells (iPSCs) or somatic cell nuclear transfer has recently emerged as a promising strategy for the development of autologous cell therapies (Goldman et al., 2012Goldman S.A. Nedergaard M. Windrem M.S. Glial progenitor cell-based treatment and modeling of neurological disease.Science. 2012; 338: 491-495Crossref PubMed Scopus (136) Google Scholar, Yamada et al., 2014Yamada M. Johannesson B. Sagi I. Burnett L.C. Kort D.H. Prosser R.W. Paull D. Nestor M.W. Freeby M. Greenberg E. et al.Human oocytes reprogram adult somatic nuclei of a type 1 diabetic to diploid pluripotent stem cells.Nature. 2014; 510: 533-536https://doi.org/10.1038/nature13287Crossref PubMed Scopus (146) Google Scholar). iPSC-derived oligodendrocyte progenitor cells (OPCs) were shown to successfully remyelinate and rescue a hypomyelinated mouse model, raising the possibility of future clinical trials (Wang et al., 2013Wang S. Bates J. Li X. Schanz S. Chandler-Militello D. Levine C. Maherali N. Studer L. Hochedlinger K. Windrem M. Goldman S.A. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination.Cell Stem Cell. 2013; 12: 252-264Abstract Full Text Full Text PDF PubMed Scopus (421) Google Scholar). However, oligodendrocyte differentiation protocols are still inefficient and require over 120 days in culture. Therefore, an improved protocol that can generate large numbers of purified OPCs in a relatively short time is highly desirable. Moreover, this protocol should be reproducible and highly efficient among different iPSC lines, including those derived from MS patients. We have pioneered the efficient and robust generation of iPSC-derived OPCs from PPMS patients. Our protocol recapitulates the major steps of oligodendrocyte differentiation from neural stem cells to OLIG2+ progenitors and finally to O4+ OPCs in a significantly shorter time than the 120–150 days required by the most recently published protocols (Wang et al., 2013Wang S. Bates J. Li X. Schanz S. Chandler-Militello D. Levine C. Maherali N. Studer L. Hochedlinger K. Windrem M. Goldman S.A. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination.Cell Stem Cell. 2013; 12: 252-264Abstract Full Text Full Text PDF PubMed Scopus (421) Google Scholar, Stacpoole et al., 2013Stacpoole S.R.L. Spitzer S. Bilican B. Compston A. Karadottir R. Chandran S. Franklin R.J.M. High yields of oligodendrocyte lineage cells from human embryonic stem cells at physiological oxygen tensions for evaluation of translational biology.Stem Cell Rep. 2013; 1: 437-450Abstract Full Text Full Text PDF Scopus (69) Google Scholar). Furthermore, O4+ OPCs were able to differentiate into MBP+ mature oligodendrocytes in vitro and to myelinate axons in vivo when injected into immunocompromised shiverer (shi/shi) mice. No abnormal growths were observed. Our results provide a proof of concept that transplantation of iPSC-derived, patient-specific cells for remyelination is technically feasible. We aimed to develop an efficient differentiation protocol that recapitulates the critical developmental stages of oligodendrocyte specification as it occurs in the spinal cord. In this process, PAX6+ neural stem cells give rise to OLIG2+ progenitors, which become committed to the oligodendrocyte lineage by coexpressing NKX2.2 (pre-OPCs). They then differentiate to early OPCs by upregulating SOX10 and PDGFRα, followed by late OPCs expressing the sulfated glycolipid antigen recognized by the O4 antibody, and finally mature to myelin basic protein (MBP)+ oligodendrocytes (Hu et al., 2009aHu B.Y. Du Z.W. Li X.J. Ayala M. Zhang S.C. Human oligodendrocytes from embryonic stem cells: conserved SHH signaling networks and divergent FGF effects.Development. 2009; 136: 1443-1452Crossref PubMed Scopus (141) Google Scholar). We utilized an OLIG2-GFP knockin human embryonic stem cell (hESC) reporter line to track the OLIG2+ progenitors by live fluorescent imaging (Liu et al., 2011Liu Y. Jiang P. Deng W. OLIG gene targeting in human pluripotent stem cells for motor neuron and oligodendrocyte differentiation.Nat. Protoc. 2011; 6: 640-655Crossref PubMed Scopus (41) Google Scholar). First, we induced PAX6+ cells using dual inhibition of SMAD signaling in adherent cultures (Chambers et al., 2009Chambers S.M. Fasano C.A. Papapetrou E.P. Tomishima M. Sadelain M. Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling.Nat. Biotechnol. 2009; 27: 275-280Crossref PubMed Scopus (2477) Google Scholar). Next, to mimic the embryonic spinal cord environment, we applied different concentrations of retinoic acid (RA) and/or sonic hedgehog (SHH) at various times and quantified the OLIG2-GFP expression by flow cytometry (Figure 1A). Application of 100 nM RA from the beginning of induction generated 40.6% of OLIG2+ progenitors, whereas addition of SHH at 100 ng/ml from day 8 increased the yield to 57.7% (Figure 1B). Interestingly, cells without exogenous SHH during the first 12 days showed an upregulation of SHH mRNA (Figure S1A available online) and differentiated to O4+ cells, although at a lower efficiency compared with cells treated with SHH (Figure S1B). We then replaced the recombinant human SHH protein with the smoothened agonist (SAG), which increased the yield further to 70.1% OLIG2+ progenitors (Figure 1B). At day 12, cells were detached for sphere aggregation. The minimum number of cells required to form a sphere was 100, and we noted that the majority of the cells in the spheres were GFP+. To investigate this further, we sorted d12 cultures for GFP and observed that only GFP+ cells formed aggregates, whereas the GFP− population did not (Figure 1C). This suggests that the aggregation step alone provides enrichment for the OLIG2+ population. Next, we validated the initial steps toward the generation of OLIG2+ progenitors by differentiating a second hESC line (RUES1) and comparing the transcript levels of PAX6, OLIG2, and NKX2.2 by quantitative RT-PCR (qRT-PCR). The upregulation of these transcription factors followed a temporal pattern similar to that of the OLIG2-GFP line, with PAX6 induction around day7, OLIG2 peak around day 13, and sustainably high levels of NKX2.2 after day 10 (Figure 1D). Based on these results, we used the nongenetically modified RUES1 line to develop the following steps of the protocol from OLIG2+ progenitors to MBP+ mature oligodendrocytes (Figure 2A). PAX6+ cells arose at day 7, and by day 12 they were arranged into multilayered structures (Figures 2B and 2C). From day 12 to day 30 the cells were grown as spheres, and they were then plated onto poly-L-ornithine/laminin-coated dishes for the remainder of the differentiation protocol. To promote maturation toward the O4+ stage, platelet-derived growth factor AA (PDGF-AA), hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF1), and neurotrophin 3 (NT3) were added to the culture medium from day 20 onward. OLIG2+ progenitors upregulated NKX2.2 (pre-OPCs) and then SOX10 (early OPCs), and they finally matured to late OPCs, which were identified by O4 live staining and by their highly ramified processes (Figures 2D–2G). O4+ OPCs expressing OLIG2, SOX10, and NG2 (Figures 2H–2J) appeared as early as day 50 and increased dramatically around day 75. During the differentiation, 40%–50% of progenitor cells were proliferative, as indicated by Ki67 staining. However, the highly ramified O4+ cells did not divide in vitro (Figures S2A–S2C). Additionally, 34% ± 4% of O4+ OPCs differentiated into MBP+ mature oligodendrocytes after growth-factor withdrawal from the medium for at least 3 weeks (Figures 2K, 2L, and S2D). Our cultures also consisted of other cell types (15% ± 2% GFAP+ astrocytes and 20% ± 2% MAP2+ neurons of total cells, respectively; Figures 2M and S2E). To determine whether this protocol could be applied to iPSC lines from subjects with PPMS, we obtained skin biopsies from four PPMS patients. Fibroblast cultures were established from the biopsies and iPSCs were generated using a cocktail of modified mRNAs (Warren et al., 2010Warren L. Manos P.D. Ahfeldt T. Loh Y.H. Li H. Lau F. Ebina W. Mandal P.K. Smith Z.D. Meissner A. et al.Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.Cell Stem Cell. 2010; 7: 618-630Abstract Full Text Full Text PDF PubMed Scopus (2034) Google Scholar) together with a cluster of miRNAs to improve the reprogramming efficiency (StemGent). From day 12 to day 15 of reprogramming, TRA-1-60+ colonies (Figure S3A), identified by live staining, were picked, expanded, and characterized by immunofluorescence for pluripotency markers (Figure S3B). Expression profiling for seven pluripotency genes confirmed that all four iPSC lines exhibited a profile comparable to that of a reference hESC line and divergent from the parental fibroblasts (Figure S3C). All iPSC lines displayed a normal karyotype (Figure S3D) and were able to differentiate into cell types of the three germ layers, both in vitro via spontaneous embryoid body differentiation (Figure S3E) and in vivo via teratoma assay (Figure S3F). Next, we assessed whether the oligodendrocyte differentiation protocol was reproducible with our PPMS-iPSC lines. All iPSC lines tested were found to perform similarly to the RUES1 line (Figures 3A–3I). The protocol was greatly reproducible and highly efficient as calculated by the frequency of sorted O4+ OPCs, with up to 70% O4+ cells from RUES1 and 43.6%–62.1% from the PPMS-iPSC lines. Additionally, we found that the O4+ fraction contained a subpopulation of cells double positive with PDGFRα (Figure 3J). O4+ cells could be easily purified by fluorescence-activated cell sorting (FACS), frozen, and thawed without losing their morphology (Figure S4D). To verify that OPCs obtained through our protocol were functionally myelinogenic, we injected d75 FACS-purified O4+ cells into the forebrain of neonatal, immunocompromised shiverer mice (105 cells/animal; Figure S4A). The injected cells were depleted of any contaminant iPSCs, as shown by flow-cytometry analysis of the pluripotency markers SSEA4 and TRA-1-60 (Figure S4B). However, we still purified our cultures before in vivo transplantation to retain the potential for translation to clinical studies. Cells were frozen, thawed, and allowed to recover for 24–48 hr before transplantation (Figure S4C). Animals were sacrificed at 12–16 weeks, at which point human hNA+ cells were distributed throughout the corpus callosum and forebrain white matter. The density of hNA+ cells in the corpus callosum was 34,400 ± 3,090 cells/mm3 at 12 weeks and approximately double that by 16 weeks. We did not observe the presence of cell clusters or overt tumorigenesis, and the proliferative fraction of engrafted hNA+ cells was 17% at 12 weeks and decreased to only 8% Ki67+ at 16 weeks when only 5% of cells were PCNA+ (Figure 4H). Importantly, more than 80% of hNA+ cells in the corpus callosum coexpressed OLIG2 protein, suggesting that the engrafted cells were restricted to the oligodendrocyte lineage (Figure 4I). Furthermore, human MBP+ oligodendrocytes were found diffusely throughout engrafted corpus callosum at 12 and 16 weeks (Figure 4A). At 16 weeks, 31% ± 3% of host mouse axons were ensheathed within the engrafted mouse corpus callosum (Figure 4B). We then asked whether PPMS-derived OPCs could form compact myelin. Transmission electron microscopy on 16-week-old corpus callosum revealed mature compact myelin with the presence of alternating major dense and intraperiod lines (Figures 4C and 4D), whereas uninjected shiverer/rag2 mice possessed thin and loosely wrapped myelin (data not shown). Likewise, the thickness of myelin ensheathment, as assessed by g-ratio measurement, reflected a restoration of normal myelin in several callosal axons. At 12 weeks, transplanted cells remained as NG2+ OPCs in the corpus callosum (Figure 4E), and by 16 weeks they started to migrate to the overlying cerebral cortex (Figure 4F). Very few O4-sorted cells underwent differentiation as hGFAP+ astrocytes and the majority of hGFAP+ cells were localized to the subventricular zone and around the ventricles (Figure 4G), suggesting that the local environment may induce astrocytic differentiation in these regions. Similarly, hNESTIN-expressing cells were rarely found in the corpus callosum and likewise concentrated in the subventricular zone (data not shown). Importantly, βIII-TUBULIN+ neurons were not detected in any of the engrafted animals. Taken together, our data demonstrate that PPMS-derived, O4-sorted cells were capable of achieving mature oligodendrocyte differentiation in vivo and forming dense compact myelin resembling normal myelin in the brain. In this work, using a fast and highly reproducible protocol, we demonstrated efficient in vivo myelination of neurons by iPSC-derived OPCs from PPMS patients. A previous report on MS-derived iPSCs showed that oligodendrocytes could be differentiated in vitro from an integrating, retrovirally reprogrammed iPSC line from one 35-year-old RRMS patient (Song et al., 2012Song B. Sun G. Herszfeld D. Sylvain A. Campanale N.V. Hirst C.E. Caine S. Parkington H.C. Tonta M.A. Coleman H.A. et al.Neural differentiation of patient specific iPS cells as a novel approach to study the pathophysiology of multiple sclerosis.Stem Cell Res. (Amst.). 2012; 8: 259-273Crossref PubMed Scopus (76) Google Scholar); here, we generated four integration-free iPSC lines from PPMS patients of both sexes and with ages ranging from 50 to 62 years. Since most protocols for oligodendrocyte differentiation have been optimized using only one or two hESC lines and their reproducibility with iPSC lines is controversial (Alsanie et al., 2013Alsanie W.F. Niclis J.C. Petratos S. Human embryonic stem cell-derived oligodendrocytes: protocols and perspectives.Stem Cells Dev. 2013; 22: 2459-2476Crossref PubMed Scopus (34) Google Scholar), we tested our protocol with two hESC and four hiPSC lines derived from PPMS patients. Previous work has elegantly shown that iPSC-derived OPCs from healthy controls were able to rescue a mouse model of hypomyelination, although differentiation to the O4 stage was rather inefficient and required more than 120 days (Wang et al., 2013Wang S. Bates J. Li X. Schanz S. Chandler-Militello D. Levine C. Maherali N. Studer L. Hochedlinger K. Windrem M. Goldman S.A. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination.Cell Stem Cell. 2013; 12: 252-264Abstract Full Text Full Text PDF PubMed Scopus (421) Google Scholar). We provide an improved differentiation protocol and further proof that patient-specific iPSC lines can be successfully used to generate oligodendrocytes. We obtained 44%–70% O4+ cells in all lines after 75 days of differentiation, compared with the minimum of 120 days required according to previous reports (Wang et al., 2013Wang S. Bates J. Li X. Schanz S. Chandler-Militello D. Levine C. Maherali N. Studer L. Hochedlinger K. Windrem M. Goldman S.A. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination.Cell Stem Cell. 2013; 12: 252-264Abstract Full Text Full Text PDF PubMed Scopus (421) Google Scholar, Stacpoole et al., 2013Stacpoole S.R.L. Spitzer S. Bilican B. Compston A. Karadottir R. Chandran S. Franklin R.J.M. High yields of oligodendrocyte lineage cells from human embryonic stem cells at physiological oxygen tensions for evaluation of translational biology.Stem Cell Rep. 2013; 1: 437-450Abstract Full Text Full Text PDF Scopus (69) Google Scholar). There are several critical differences between our approach and previously published protocols. First, we began neural induction with dual SMAD inhibition in adherent as opposed to suspension cultures (Nistor et al., 2005Nistor G.I. Totoiu M.O. Haque N. Carpenter M.K. Keirstead H.S. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation.Glia. 2005; 49: 385-396Crossref PubMed Scopus (489) Google Scholar, Hu et al., 2009bHu B.Y. Du Z.W. Zhang S.C. Differentiation of human oligodendrocytes from pluripotent stem cells.Nat. Protoc. 2009; 4: 1614-1622Crossref PubMed Scopus (199) Google Scholar, Wang et al., 2013Wang S. Bates J. Li X. Schanz S. Chandler-Militello D. Levine C. Maherali N. Studer L. Hochedlinger K. Windrem M. Goldman S.A. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination.Cell Stem Cell. 2013; 12: 252-264Abstract Full Text Full Text PDF PubMed Scopus (421) Google Scholar). Using this approach, we started with only 10,000 cells/cm2 of iPSCs at day 0 and achieved a great expansion of neural progenitors, ultimately generating an abundance of human OPCs. The use of RA and SHH as caudalizing and ventralizing patterning agents recapitulates the signals that are present around the pMN domain of the spinal cord, from which motor neurons and oligodendrocytes are believed to arise (Hu et al., 2009aHu B.Y. Du Z.W. Li X.J. Ayala M. Zhang S.C. Human oligodendrocytes from embryonic stem cells: conserved SHH signaling networks and divergent FGF effects.Development. 2009; 136: 1443-1452Crossref PubMed Scopus (141) Google Scholar). The high efficiency in the generation of OLIG2+ cells at d12 can be explained by the synergistic effect of activin/nodal receptor kinase inhibition, BMP4 inhibition, and RA and SHH signaling (Patani et al., 2011Patani R. Hollins A.J. Wishart T.M. Puddifoot C.A. Alvarez S. de Lera A.R. Wyllie D.J. Compston D.A. Pedersen R.A. Gillingwater T.H. et al.Retinoid-independent motor neurogenesis from human embryonic stem cells reveals a medial columnar ground state.Nat. Commun. 2011; 2: 214Crossref PubMed Scopus (64) Google Scholar, Miller et al., 2004Miller R.H. Dinsio K. Wang R. Geertman R. Maier C.E. Hall A.K. Patterning of spinal cord oligodendrocyte development by dorsally derived BMP4.J. Neurosci. Res. 2004; 76: 9-19Crossref PubMed Scopus (67) Google Scholar). The optimal concentration of RA in our hands is 100 times less than the concentration commonly used by other groups (Nistor et al., 2005Nistor G.I. Totoiu M.O. Haque N. Carpenter M.K. Keirstead H.S. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation.Glia. 2005; 49: 385-396Crossref PubMed Scopus (489) Google Scholar, Izrael et al., 2007Izrael M. Zhang P. Kaufman R. Shinder V. Ella R. Amit M. Itskovitz-Eldor J. Chebath J. Revel M. Human oligodendrocytes derived from embryonic stem cells: effect of noggin on phenotypic differentiation in vitro and on myelination in vivo.Mol. Cell. Neurosci. 2007; 34: 310-323Crossref PubMed Scopus (144) Google Scholar, Gil et al., 2009Gil J.E. Woo D.H. Shim J.H. Kim S.E. You H.J. Park S.H. Paek S.H. Kim S.K. Kim J.H. Vitronectin promotes oligodendrocyte differentiation during neurogenesis of human embryonic stem cells.FEBS Lett. 2009; 583: 561-567Abstract Full Text Full Text PDF PubMed Scopus (43) Google Scholar, Hu et al., 2009bHu B.Y. Du Z.W. Zhang S.C. Differentiation of human oligodendrocytes from pluripotent stem cells.Nat. Protoc. 2009; 4: 1614-1622Crossref PubMed Scopus (199) Google Scholar). Surprisingly, induction with RA alone (without exogenous SHH) generated a large population of OLIG2+ cells. While the combination of RA and fibroblast growth factor (FGF) signaling is known to promote OLIG2 expression during chicken development and has been used for in vitro differentiation of both hESCs and hiPSCs (Novitch et al., 2003Novitch B.G. Wichterle H. Jessell T.M. Sockanathan S. A requirement for retinoic acid-mediated transcriptional activation in ventral neural patterning and motor neuron specification.Neuron. 2003; 40: 81-95Abstract Full Text Full Text PDF PubMed Scopus (265) Google Scholar, Nistor et al., 2005Nistor G.I. Totoiu M.O. Haque N. Carpenter M.K. Keirstead H.S. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation.Glia. 2005; 49: 385-396Crossref PubMed Scopus (489) Google Scholar, Pouya et al., 2011Pouya A. Satarian L. Kiani S. Javan M. Baharvand H. Human induced pluripotent stem cells differentiation into oligodendrocyte progenitors and transplantation in a rat model of optic chiasm demyelination.PLoS One. 2011; 6: e27925Crossref PubMed Scopus (66) Google Scholar), we achieved OLIG2 induction in the absence of any exogenous FGF in our culture conditions. We show that RA, synergistically with the dual inhibition of SMAD proteins, upregulates OLIG2 (Figure S1C), possibly by stimulating the endogenous expression of SHH (Figure S1A). We confirmed that SAG is an efficient replacement for SHH and indeed showed superior efficacy in our hands (Stacpoole et al., 2013Stacpoole S.R.L. Spitzer S. Bilican B. Compston A. Karadottir R. Chandran S. Franklin R.J.M. High yields of oligodendrocyte lineage cells from human embryonic stem cells at physiological oxygen tensions for evaluation of translational biology.Stem Cell Rep. 2013; 1: 437-450Abstract Full Text Full Text PDF Scopus (69) Google Scholar). The addition of HGF to the medium, although not essential, appeared to slightly improve the differentiation efficiency (data not shown; Hu et al., 2009cHu Z. Li T. Zhang X. Chen Y. Hepatocyte growth factor enhances the generation of high-purity oligodendrocytes from human embryonic stem cells.Differentiation. 2009; 78: 177-184Crossref PubMed Scopus (20) Google Scholar). Finally, the transition from adherent cultures to spheres proved to be a critical step to enrich the OLIG2+ population and possibly restrict differentiation to the oligodendrocyte lineage. In human development, OPCs are characterized by PDGFRα and NG2 expression, followed by expression of O4 (Jakovcevski et al., 2009Jakovcevski I. Filipovic R. Mo Z. Rakic S. Zecevic N. Oligodendrocyte development and the onset of myelination in the human fetal brain.Front Neuroanat. 2009; 3: 5Crossref PubMed Scopus (211) Google Scholar). Under our culture conditions, by day 75, most of the O4+ cells had lost PDGFRα, but retained NG2 expression. At this stage, we did not observe any residual pluripotent cells in culture. Our study differs from recent work in that our iPSC lines were derived from PPMS patients and the cells used for in vivo transplantation were sorted using the late-OPC marker O4 to maximally restrict the differentiation potential. Despite these differences, the PPMS-derived, O4+-sorted OPCs exhibited a similar engraftment efficiency, mitotic fraction, and proportion of host ensheathed axons while generating fewer GFAP+ astrocytes compared with the unsorted iPSC-derived OPCs reported previously. Taken together, our data suggest that PPMS-derived OPCs performed in vivo at least as efficiently as healthy iPSC-derived cells (Wang et al., 2013Wang S. Bates J. Li X. Schanz S. Chandler-Militello D. Levine C. Maherali N. Studer L. Hochedlinger K. Windrem M. Goldman S.A. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination.Cell Stem Cell. 2013; 12: 252-264Abstract Full Text Full Text PDF PubMed Scopus (421) Google Scholar). These proof-of-principle experiments establish that our OPC induction protocol can generate myelinogenic oligodendrocytes from patient samples and may be useful for the development of autologous cell-replacement therapies for MS in the future. iPSC technology is also emerging as a tool for developing new drugs and gaining insight into disease pathogenesis (Han et al., 2011Han S.S.W. Williams L.A. Eggan K.C. Constructing and deconstructing stem cell models of neurological disease.Neuron. 2011; 70: 626-644Abstract Full Text Full Text PDF PubMed Scopus (122) Google Scholar). Our differentiation protocol will aid the development of high-throughput in vitro screens for compounds that promote myelination (Lee et al., 2013Lee S. Chong S.Y. Tuck S.J. Corey J.M. Chan J.R. A rapid and reproducible assay for modeling myelination by oligodendrocytes using engineered nanofibers.Nat. Protoc. 2013; 8: 771-782Crossref PubMed Scopus (91) Google Scholar). Furthermore, the PPMS iPSC lines described here provide an additional resource for investigating the process of neurodegeneration in MS. Future studies comparing PPMS iPSCs and appropriate healthy control iPSC lines will be needed to shed light on the potential intrinsic differences among patient-derived oligodendrocytes. Skin biopsies were obtained from deidentified PPMS patients at the Tisch Multiple Sclerosis Research Center of New York, upon institutional review board approval (BRANY) and receipt of informed consent. All four patients were diagnosed with PPMS according to the standard diagnostic criteria. All patients were Caucasian. Two patients were male (56 and 61 years old) and two were female (62 and 50 years old). Three hESC lines and four hiPSC lines were used for the study. RUES1 and HUES 45 are both NIH-approved hESC lines. The OLIG2-GFP reporter line is derived from the BG01 hESC line and was a gift from Dr. Ying Liu (University of Texas Health Science Center at Houston). Four iPSC lines were derived in our laboratory from skin biopsies of PPMS patients through the mRNA/miRNA method (StemGent). hESCs and hiPSCs were induced to neural differentiation through dual SMAD inhibition together with 100 nM all-trans RA. At day 8, SAG (1 μM) was added to the medium, and at day 12, adherent cells were lifted and seeded in low-attachment plates to favor sphere aggregation. Spheres were cultured in the presence of RA and SAG. At day 30, spheres were plated into poly-L-ornithine/laminin-coated dishes and cells were allowed to migrate out of the sphere. At this stage, PDGF medium was used to promote OPC formation, and from day 75 onward, glial medium was used to drive oligodendrocyte maturation. For the qRT-PCR primer sequences and media compositions used, see Tables S1 and S2, respectively. All experiments using shiverer/rag2 mice (a gift from Dr. Steven A. Goldman, University of Rochester; Windrem et al., 2008Windrem M.S. Schanz S.J. Guo M. Tian G.F. Washco V. Stanwood N. Rasband M. Roy N.S. Nedergaard M. Havton L.A. et al.Neonatal chimerization with human glial progenitor cells can both remyelinate and rescue the otherwise lethally hypomyelinated shiverer mouse.Cell Stem Cell. 2008; 2: 553-565Abstract Full Text Full Text PDF PubMed Scopus (240) Google Scholar) were performed according to protocols approved by the University at Buffalo Institutional Animal Care and Use Committee. Injections were performed as previously described (Sim et al., 2011Sim F.J. McClain C.R. Schanz S.J. Protack T.L. Windrem M.S. Goldman S.A. CD140a identifies a population of highly myelinogenic, migration-competent and efficiently engrafting human oligodendrocyte progenitor cells.Nat. Biotechnol. 2011; 29: 934-941Crossref PubMed Scopus (153) Google Scholar) and the animals were sacrificed 12–16 weeks later. Cryopreserved coronal sections were cut and immunohistochemistry was performed as described previously (Sim et al., 2011Sim F.J. McClain C.R. Schanz S.J. Protack T.L. Windrem M.S. Goldman S.A. CD140a identifies a population of highly myelinogenic, migration-competent and efficiently engrafting human oligodendrocyte progenitor cells.Nat. Biotechnol. 2011; 29: 934-941Crossref PubMed Scopus (153) Google Scholar). For transmission electron microscopy, tissue was processed as described previously (Sim et al., 2002Sim F.J. Zhao C. Li W.W. Lakatos A. Franklin R.J. Expression of the POU-domain transcription factors SCIP/Oct-6 and Brn-2 is associated with Schwann cell but not oligodendrocyte remyelination of the CNS.Mol. Cell. Neurosci. 2002; 20: 669-682Crossref PubMed Scopus (39) Google Scholar). For a list of the primary antibodies used, see Table S3. We thank Drs. Dieter Egli and Haiqing Hua for the teratoma study and Dr. Ana Sevilla and Chris Woodard for the nanostring analysis. This work was supported by an NYSCF-Helmsley Early Career Investigator Award, The New York Stem Cell Foundation, and The Leona M. and Harry B. Helmsley Charitable Trust. In vivo studies were supported by the Empire State Stem Cell Fund through the New York State Department of Health (contract C028108 to F.J.S.). Download .pdf (.55 MB) Help with pdf files Document S1. Supplemental Experimental Procedures, Figures S1–S4, and Tables S1–S3" @default.
• W2094539666 created "2016-06-24" @default.
• W2094539666 creator A5011457832 @default.
• W2094539666 creator A5021404394 @default.
• W2094539666 creator A5030115588 @default.
• W2094539666 creator A5037677450 @default.
• W2094539666 creator A5039125752 @default.
• W2094539666 creator A5051907184 @default.
• W2094539666 creator A5058918658 @default.
• W2094539666 creator A5062224882 @default.
• W2094539666 creator A5067267565 @default.
• W2094539666 date "2014-08-01" @default.
• W2094539666 modified "2023-10-09" @default.
• W2094539666 title "Efficient Generation of Myelinating Oligodendrocytes from Primary Progressive Multiple Sclerosis Patients by Induced Pluripotent Stem Cells" @default.
• W2094539666 cites W1481663166 @default.
• W2094539666 cites W1977543000 @default.
• W2094539666 cites W1980775054 @default.
• W2094539666 cites W1988756396 @default.
• W2094539666 cites W1994285313 @default.
• W2094539666 cites W2005760116 @default.
• W2094539666 cites W2005932654 @default.
• W2094539666 cites W2006598219 @default.
• W2094539666 cites W2018440098 @default.
• W2094539666 cites W2026547662 @default.
• W2094539666 cites W2027669322 @default.
• W2094539666 cites W2032054191 @default.
• W2094539666 cites W2032625959 @default.
• W2094539666 cites W2045923526 @default.
• W2094539666 cites W2054064334 @default.
• W2094539666 cites W2056915271 @default.
• W2094539666 cites W2062065025 @default.
• W2094539666 cites W2072068036 @default.
• W2094539666 cites W2076152867 @default.
• W2094539666 cites W2078436875 @default.
• W2094539666 cites W2087786585 @default.
• W2094539666 cites W2088377755 @default.
• W2094539666 cites W2098597036 @default.
• W2094539666 cites W2121554658 @default.
• W2094539666 cites W2131960843 @default.
• W2094539666 cites W2136231875 @default.
• W2094539666 cites W2150136533 @default.
• W2094539666 cites W2168579634 @default.
• W2094539666 doi "https://doi.org/10.1016/j.stemcr.2014.06.012" @default.
• W2094539666 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4176529" @default.
• W2094539666 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25254339" @default.
• W2094539666 hasPublicationYear "2014" @default.
• W2094539666 type Work @default.
• W2094539666 sameAs 2094539666 @default.
• W2094539666 citedByCount "240" @default.
• W2094539666 countsByYear W20945396662014 @default.
• W2094539666 countsByYear W20945396662015 @default.
• W2094539666 countsByYear W20945396662016 @default.
• W2094539666 countsByYear W20945396662017 @default.
• W2094539666 countsByYear W20945396662018 @default.
• W2094539666 countsByYear W20945396662019 @default.
• W2094539666 countsByYear W20945396662020 @default.
• W2094539666 countsByYear W20945396662021 @default.
• W2094539666 countsByYear W20945396662022 @default.
• W2094539666 countsByYear W20945396662023 @default.
• W2094539666 crossrefType "journal-article" @default.
• W2094539666 hasAuthorship W2094539666A5011457832 @default.
• W2094539666 hasAuthorship W2094539666A5021404394 @default.
• W2094539666 hasAuthorship W2094539666A5030115588 @default.
• W2094539666 hasAuthorship W2094539666A5037677450 @default.
• W2094539666 hasAuthorship W2094539666A5039125752 @default.
• W2094539666 hasAuthorship W2094539666A5051907184 @default.
• W2094539666 hasAuthorship W2094539666A5058918658 @default.
• W2094539666 hasAuthorship W2094539666A5062224882 @default.
• W2094539666 hasAuthorship W2094539666A5067267565 @default.
• W2094539666 hasBestOaLocation W20945396661 @default.
• W2094539666 hasConcept C104317684 @default.
• W2094539666 hasConcept C107459253 @default.
• W2094539666 hasConcept C121332964 @default.
• W2094539666 hasConcept C1276947 @default.
• W2094539666 hasConcept C136834591 @default.
• W2094539666 hasConcept C145103041 @default.
• W2094539666 hasConcept C169760540 @default.
• W2094539666 hasConcept C203014093 @default.
• W2094539666 hasConcept C2777977315 @default.
• W2094539666 hasConcept C2780640218 @default.
• W2094539666 hasConcept C28328180 @default.
• W2094539666 hasConcept C54355233 @default.
• W2094539666 hasConcept C86803240 @default.
• W2094539666 hasConcept C95444343 @default.
• W2094539666 hasConceptScore W2094539666C104317684 @default.
• W2094539666 hasConceptScore W2094539666C107459253 @default.
• W2094539666 hasConceptScore W2094539666C121332964 @default.
• W2094539666 hasConceptScore W2094539666C1276947 @default.
• W2094539666 hasConceptScore W2094539666C136834591 @default.
• W2094539666 hasConceptScore W2094539666C145103041 @default.
• W2094539666 hasConceptScore W2094539666C169760540 @default.
• W2094539666 hasConceptScore W2094539666C203014093 @default.
• W2094539666 hasConceptScore W2094539666C2777977315 @default.
• W2094539666 hasConceptScore W2094539666C2780640218 @default.
• W2094539666 hasConceptScore W2094539666C28328180 @default.
• W2094539666 hasConceptScore W2094539666C54355233 @default.
• W2094539666 hasConceptScore W2094539666C86803240 @default.
• W2094539666 hasConceptScore W2094539666C95444343 @default.

• next